Stock Comparison

CRMD vs JNJ

CorMedix Inc vs Johnson & Johnson

The Verdict

CRMD takes this one.

Winner

CRMD

CorMedix Inc

8.9

out of 10

Hidden Gem

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Head-to-Head

$646M

Market Cap

$557.1B

3.6

P/E Ratio

26.5

45.3%

Profit Margin

21.8%

50.4%

Return on Equity

26.3%

0.4

Debt-to-Equity

0.6

Moderate

Overall Risk

Conservative

8.9

DVR Score

1.0

The Deep Dive

CRMD8.9/10

CorMedix Inc. exhibits significantly de-risked commercialization with exceptional Q1 2026 results, reporting $127.4 million in revenue and $38.6 million in net income, handily beating revenue estimates. The company substantially raised its FY2026 guidance to $325M-$345M revenue and $115M-$135M adjusted EBITDA, demonstrating strong market adoption of DefenCath and effective integration of the Melin...

Full CRMD Analysis

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Full JNJ Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.